Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference
WOBURN, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Executive Chairman and …